Largest ever Lassa fever study expands to more countries in West Africa

Sat, Jul 31, 2021
By editor
11 MIN READ

Health

CEPI is providing US$ 10.3 million in funding to partners in Benin, Guinea, Liberia, and Sierra Leone to  participate in the epidemiological research programme Enable, which will enrol up to 23,000  participants, including Nigeria, which began collecting participant data in December 2020. The in country partners selected for the research are Fondation pour la Recherche Scientifique (FORS) in  Benin, Phebe Hospital in partnership with the National Public Health Institute of Liberia (NPHIL) in  Liberia, supported by University of North Carolina at Chapel Hill (UNC), Kenema Government Hospital  in Sierra Leone (KGH) in cooperation with Tulane University, and Université Gamal Nasser de Conakry  (UGANC) in Guinea, in partnership with Robert Koch Institut (RKI).

First identified in 1969, Lassa fever is a potentially deadly haemorrhagic illness occurring across West  Africa, with an estimated 1% of cases proving fatal. It is listed on the World Health Organization  (WHO) R&D Blueprint as an emerging infectious disease in urgent need of research and development  and is also recognised in CEPI’s ambitious $3.5bn plan to tackle future epidemics and pandemics  caused by known and unknown threats.

However, our current knowledge on the annual Lassa case rate is hindered by a lack of formal and  standard clinical diagnoses for the illness and significant variability and severity in symptoms, with  the majority of patients who become infected thought to be asymptomatic and failing to seek  diagnosis. Cases may also occur in remote regions where there are difficulties in accessing health care  services for testing. As a result, the true case count is unknown and likely to be much higher than  current estimates of 100,000 to 300,000 cases per year.

The Enable study therefore aims to better understand the rate, location, and spread of Lassa virus  across the region. Data collected in the countries will highlight any differences in the age and gender of  people who become infected, while also providing a more accurate overview on the proportion of  asymptomatic and symptomatic cases.

In addition, results from Enable will be crucial in supporting CEPI’s goal, as part of its five-year lookahead strategy, of producing a licenced Lassa vaccine for routine immunisation. As a leading  funder of Lassa vaccine development, CEPI has already supported the development of six Lassa  vaccine candidates. Two of these vaccines, developed by partners Inovio and Themis Bioscience,  entered Phase I trials in 2019, and a further vaccine candidate, developed by IAVI, started in-human  testing this year.

1

Data provided from the Enable research programme may therefore guide the location and  implementation of future late-stage efficacy trials to evaluate these or other Lassa vaccine candidates. It could also help to define an appropriate vaccination strategy once a Lassa vaccine is approved for  use, for example by helping to identify priority populations at risk.

The research will also support another goal in CEPI’s five-year plan assisting countries with  developing the infrastructure and expertise to undertake the epidemiological and clinical studies  needed to advance vaccine development and enable such countries to take full ownership of their  national health security.

“There have been a number of positive developments in the Lassa vaccine space over the past couple of  years, with multiple candidates now moving into in-human testing” said Dr Melanie Saville, Director  of Vaccine Research & Development at CEPI.

“To continue this momentum and to meet CEPI’s goal to get a licenced Lassa vaccine for routine  immunisation, we must therefore now advance our disease-assessment efforts to provide the critical  data for future late-stage Lassa vaccine clinical trials. The results produced by the Enable research  programme will be vital in contributing to this endeavour, while also providing novel information to  help support healthcare workers and researchers in the region working on this potentially deadly  threat.”

Enable research partners will collect data on potential infections either through ‘active case follow-up’, whereby a field worker carries out repeat health assessments on study participants through home  visits or phone meetings to assess the health status of participants, or ‘passive case detection’, where  participants will be encouraged to report potential illness or to self-present at a health facility and the  suspected or confirmed case is then recorded.

A subset of those enrolled will also take part in an additional assessment to look at the prevalence of  Lassa fever antibodies–biomarkers of the immune response–among participants. This will act as an  indicator to better guide estimates of how many individuals in the general population are likely to have  previously been infected with the virus and are, at present, protected against (immune from) the  disease; it is generally assumed that a single infection with Lassa fever virus will produce life-long  protective immunity.

Prof. Ayola Akim Adegnika, MD PhD MSc, Principal Investigator, FORS Benin, said: “I am delighted to  be part of the Lassa fever study in West Africa. This rigorous scientific study will allow us to collect  precise data to allow the country and partners to plan evidence-based interventions and controls.”

Dr. Jefferson Sibley, Phebe Hospital Medical Director, Liberia, said: “There were challenges when we  first started, and bottlenecks we’ve encountered, especially encouraging people in our culture to  participate in research studies. But our team has been working to enroll participants and we’re  learning lessons as we go; in fact, as we go, our study is progressing better than we could have  imagined. Our participants have expressed the pride they have in Liberia, and in their communities, for  playing a role in a future that could ultimately be Lassa free.”

Dr. Robert Garry, Tulane University, co-principal investigator working in cooperation with Kenema  Government Hospital in Sierra Leone, said: “CEPI’s program to assess the incidence of Lassa virus  infections in West Africa has been meticulously planned. These essential epidemiological studies will  provide the foundation for clinical trials of promising Lassa vaccines that have to potential to achieve  control of this massive public health threat.”

Seven thousand participants have already been recruited into the Nigerian component of the Enable programme, led by the Nigeria Lassa fever Research Consortium consisting of the Nigeria Centre for

2

Disease Control (NCDC) and supporting partners. As part of CEPI’s access commitments, data for both  the Nigerian study and programmes announced today will be made available to partners and the public  via peer-reviewed open-access publications and via CEPI’s hub on The Global Health Network.

Dr Chikwe Ihekweazu, Director-General, Nigeria Centre for Disease Control (NCDC) Nigeria, said:  “The Enable Lassa programme is building on collaboration among countries in West Africa most  affected by Lassa fever to generate data and evidence that we urgently need for vaccine R&D. We are  excited about the prospects of the project, not only in generating data for vaccine development, but  also in strengthening our knowledge of the epidemiology of this disease and improving on the much needed interventions for disease control.”

The study methodology and protocol were devised in collaboration with the coordinating partners who  are now supporting the participating countries during implementation. All will follow a harmonised core protocol and methods to allow for standardised recording and comparability of data across the  countries. Coordinating institutions supporting the overall Enable programme implementation include  P-95, Margan Clinical Research Organization (MMARCRO), Epicentre, and the Bernard Nocht Institute  for Tropical Medicine (BNITM).

-ENDS-

 

About Lassa fever and Lassa vaccine development

Lassa haemorrhagic fever is spread through contact with the infected rodent host Mastomys natalensis, or from  person-to-person contact via bodily fluids. It is a zoonotic viral infection found predominantly in West Africa. The  majority of patients who become infected with Lassa virus infection are asymptomatic; however, in some cases the  disease may progress to more serious symptoms including fever, vomiting, body pains, and haemorrhaging. Death  may occur within two weeks after symptom onset due to multi-organ failure. Further information on Lassa fever  can be found in the ‘Lassa fever Disease Factfile’ on our website.

There are no licenced vaccines or treatments specifically for Lassa. CEPI currently has 6 Lassa vaccine candidates in  its portfolio – with Emergent Biosolutions & PATH, Inovio Pharmaceuticals, International AIDS Vaccine Initiative  (IAVI), Themis Bioscience, Janssen Vaccines & University of Oxford, and CureVac. Inovio’s Lassa fever candidate  entered Phase I clinical trials in May 2019. Themis Bioscience’s initiated Phase I clinical trials with its Lassa fever  vaccine candidate in October 2019. CEPI and its partner, the European & Developing Countries Clinical Trials  Partnership (EDCTP), recently announced additional funding for a Phase IIb trial assessing IAVI’s Lassa vaccine  candidate in endemic countries. Its Phase I vaccine study launched this year.

About the Enable Lassa research programme

The Enable Lassa research programme study site partners are:

  • BENIN Fondation pour la Recherche Scientifique (FORS)
  • LIBERIA Co-led by University of North Carolina at Chapel Hill (UNC) and Phebe Hospital in partnership with  the National Public Health Institute of Liberia (NPHIL)
  • GUINEA Université Gamal Nasser de Conakry (UGANC) in partnership with Robert Koch Institut (RKI) • NIGERIA Nigeria Centre for Disease Control (NCDC), Irrua Specialist Teaching Hospital (ISTH), Federal  Medical Centre (FMC) Owo, Alex Ekwueme Federal University Teaching Hospital Abakaliki (AEFUTHA),  Redeemer’s University Nigeria (RUN) and the African Field Epidemiology Network (AFENET). Together, the  Nigerian partners make up the NiLE project of Enable.
  • SIERRA LEONE Co-led by Kenema Government Hospital (KGH) and Tulane University

A total of US $26 million in funding has been made available across the programme. CEPI is providing US$ 10.3  million in funding to expand the study to Benin, Guinea, Liberia, and Sierra Leone.

CEPI will work as a funder and facilitator, supporting the financing of the programme as well as supporting a  country-led governance framework and forging key links to the global scientific and vaccine development  communities.

Enable partners were first selected following Calls for Proposals, published by CEPI in 2018 and 2019, which sought  groups with extensive Lassa research and field research experience across West Africa.

3

A workshop was first held in January 2019 in Abuja, Nigeria, to engage study sites in the creation of the shared  protocol for the studies and to inform and obtain feedback from partners on the next steps in the development of  the programme.

In addition to the country partners, CEPI has selected four implementing partners to support the execution and  oversight of the Enable programme. P-95 acts as programme coordinator, providing scientific and operational  oversight to all coordinating partners and country study implementation teams as well as programme-level project  management. The Margan Clinical Research Organization (MMARCRO), based in Accra, Ghana, supports P-95  through in-country field implementation and study monitoring support. Epicentre, a Paris-based organization  conducting field epidemiology activities, research projects and training sessions in support of Médecins Sans  Frontières (MSF); leads development of the programme data management system; is providing training and  support to staff operating at Enable study sites; and is supervising the data collection, management, and analysis  processes. The Bernard Nocht Institute for Tropical Medicine, based in Hamburg, Germany, supports the Enable programme through laboratory expertise and support to country implementing partners, including staff training,  laboratory process development, and quality assurance.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos  in 2017, to develop vaccines against future epidemics. Prior to COVID-19 CEPI’s work focused on developing  vaccines against Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley  Fever virus and Chikungunya virus – it has over 20 vaccine candidates against these pathogens in development.  CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens  (Disease X).

During the current pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its  variants with a focus on speed, scale and access. These programmes leverage the rapid response platforms  previously developed by CEPI’s partners prior to the emergence of COVID-19 as well as new collaborations. The aim  is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable  fair allocation to these vaccines worldwide through COVAX.

CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop  a universal vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for  use against known and unknown pathogens. The plan is available at endpandemics.cepi.net.

Follow our news page for the latest updates. Follow us on Twitter and LinkedIn.

– July 31, 2021 @ 16:58 GMT |

Tags: